These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 20001169

  • 1. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit.
    Rodin HA, Heaton AH, Wilson AR, Garrett NA, Plocher DW.
    Am J Manag Care; 2009 Dec; 15(12):881-8. PubMed ID: 20001169
    [Abstract] [Full Text] [Related]

  • 2. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL, Cox ER.
    Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
    [Abstract] [Full Text] [Related]

  • 3. Impact of alternative interventions on changes in generic dispensing rates.
    O'Malley AJ, Frank RG, Kaddis A, Rothenberg BM, McNeil BJ.
    Health Serv Res; 2006 Oct; 41(5):1876-94. PubMed ID: 16987306
    [Abstract] [Full Text] [Related]

  • 4. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA, Avorn J.
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [Abstract] [Full Text] [Related]

  • 5. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation.
    Motheral BR, Henderson R.
    Am J Manag Care; 1999 Nov; 5(11):1383-94. PubMed ID: 10662412
    [Abstract] [Full Text] [Related]

  • 6. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate.
    Mager DE, Cox ER.
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):347-52. PubMed ID: 17567235
    [Abstract] [Full Text] [Related]

  • 7. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
    Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, Dirstine J, Avorn J, Asch SM.
    Arch Intern Med; 2006 Feb 13; 166(3):332-7. PubMed ID: 16476874
    [Abstract] [Full Text] [Related]

  • 8. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S, Barbeau M.
    Curr Med Res Opin; 2004 Apr 13; 20(4):453-9. PubMed ID: 15119982
    [Abstract] [Full Text] [Related]

  • 9. Effect of generic-only drug benefits on seniors' medication use and financial burden.
    Tseng CW, Brook RH, Keeler E, Steers WN, Waitzfelder BE, Mangione CM.
    Am J Manag Care; 2006 Sep 13; 12(9):525-32. PubMed ID: 16961441
    [Abstract] [Full Text] [Related]

  • 10. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use.
    Shrank WH, Stedman M, Ettner SL, DeLapp D, Dirstine J, Brookhart MA, Fischer MA, Avorn J, Asch SM.
    J Gen Intern Med; 2007 Sep 13; 22(9):1298-304. PubMed ID: 17647066
    [Abstract] [Full Text] [Related]

  • 11. Controlling prescription drug expenditures: a report of success.
    Miller DP, Furberg CD, Small RH, Millman FM, Ambrosius WT, Harshbarger JS, Ohl CA.
    Am J Manag Care; 2007 Aug 13; 13(8):473-80. PubMed ID: 17685828
    [Abstract] [Full Text] [Related]

  • 12. The effect of generic competition on the price of brand-name drugs.
    Lexchin J.
    Health Policy; 2004 Apr 13; 68(1):47-54. PubMed ID: 15033552
    [Abstract] [Full Text] [Related]

  • 13. Generic substitution of antihypertensive drugs: does it affect adherence?
    Van Wijk BL, Klungel OH, Heerdink ER, de Boer A.
    Ann Pharmacother; 2006 Jan 13; 40(1):15-20. PubMed ID: 16303985
    [Abstract] [Full Text] [Related]

  • 14. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB, Frial T, Miller PS.
    Can J Clin Pharmacol; 2007 Jan 13; 14(2):e205-14. PubMed ID: 17556788
    [Abstract] [Full Text] [Related]

  • 15. Managing drug costs: the perception of managed care pharmacy directors.
    Litton LM, Sisk FA, Akins ME.
    Am J Manag Care; 2000 Jul 13; 6(7):805-14. PubMed ID: 11067377
    [Abstract] [Full Text] [Related]

  • 16. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF, Merrell K, Hargrave E, Summer L.
    Health Aff (Millwood); 2012 Oct 13; 31(10):2266-75. PubMed ID: 23048108
    [Abstract] [Full Text] [Related]

  • 17. Effect of prescription benefit changes on medical care utilization in a Medicare HMO population.
    Balkrishnan R, Byerly WG, Camacho FT, Shrestha A, Anderson RT.
    Am J Manag Care; 2001 Nov 13; 7(11):1093-100. PubMed ID: 11725812
    [Abstract] [Full Text] [Related]

  • 18. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
    Tungol A, Starner CI, Gunderson BW, Schafer JA, Qiu Y, Gleason PP.
    J Manag Care Pharm; 2012 Nov 13; 18(9):690-700. PubMed ID: 23206212
    [Abstract] [Full Text] [Related]

  • 19. Impact of patient and plan design factors on switching to preferred statin therapy.
    Cox ER, Kulkarni A, Henderson R.
    Ann Pharmacother; 2007 Dec 13; 41(12):1946-53. PubMed ID: 17971409
    [Abstract] [Full Text] [Related]

  • 20. Reducing patient drug acquisition costs can lower diabetes health claims.
    Mahoney JJ.
    Am J Manag Care; 2005 Aug 13; 11(5 Suppl):S170-6. PubMed ID: 16111439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.